Affimed (NASDAQ:AFMD) Sees Significant Decline in Short Interest

Affimed (NASDAQ:AFMD) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 742,900 shares, a drop of 12.3% from the December 15th total of 846,900 shares. Based on an average daily volume of 291,200 shares, the days-to-cover ratio is currently 2.6 days. Approximately 5.7% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research firms recently issued reports on AFMD. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Stifel Nicolaus cut their price target on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a report on Friday, November 15th. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Affimed Stock Performance

Shares of Affimed stock opened at $1.15 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $2.05 and a 200-day moving average price of $3.35. Affimed has a one year low of $1.03 and a one year high of $8.95.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Affimed in the 3rd quarter worth approximately $44,000. Choreo LLC purchased a new position in shares of Affimed in the 2nd quarter worth approximately $54,000. Point72 Asset Management L.P. boosted its holdings in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after purchasing an additional 15,108 shares during the period. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the period. Finally, FMR LLC lifted its stake in shares of Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.